{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962797",
  "id": "02962797",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250627",
  "time": "0930",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250627/pdf/06l5g31f1vlzss.pdf",
  "summary": "**Clinical Trial Update (Phase II Study):**  \n- First patient dosed in **Phase II Neo-POLEM trial** (investigator-sponsored) for **PD1-Vaxx**, a neoadjuvant immunotherapy targeting **dMMR/MSI-high colorectal cancer**.  \n- **Primary endpoint**: Major pathological response rates (tumor reduction post-treatment before surgery).  \n- **Trial locations**: Australia (Queen Elizabeth Hospital) and UK, with recruitment ongoing.  \n- **Market context**: Colorectal cancer is the **3rd most common cancer globally**, with ~15% of cases being dMMR/MSI-high subtype.  \n\n*No material financial or trading-specific information disclosed (e.g., funding, timelines, or capital impact).*",
  "usage": {
    "prompt_tokens": 1388,
    "completion_tokens": 154,
    "total_tokens": 1542,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-26T23:47:52.935553"
}